Beta Bionics vs Outset Medical
Outset Medical is the larger business, with $119m of revenue in fiscal 2025 against $100m for Beta Bionics (1.2 times as much). Beta Bionics grew faster (53.9% against 5.1%). Outset Medical kept more of each dollar of sales as profit: a net margin of -68.3% against -73.0%. Beta Bionics carries less debt relative to equity (0.0% against 75.8%).
| Latest fiscal year | Beta BionicsBBNX, 2025 | Outset MedicalOM, 2025 |
|---|---|---|
| Revenue | $100m | $119m |
| Revenue growth | 53.9% | 5.1% |
| Net income | −$73.2m | −$81.7m |
| Operating margin | -71.5% | -55.8% |
| Net margin | -73.0% | -68.3% |
| Return on equity | — | -106.2% |
| Free cash flow | −$56.2m | −$47.1m |
| Cash | $31.6m | $35.0m |
| Total debt | $0 | $96.2m |
| Debt to equity | 0.0% | 75.8% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 420 | 254 |
| Market value | $817m | $76.3m |
| Price vs our value range | — | — |
| Moat score | — | 12 (Weak) |
| Insider trades, 12 months | 0 buys, 52 sales | 2 buys, 23 sales |